Quotes 5-day view Delayed Nasdaq
11/19/2020
11/20/2020
11/23/2020
11/24/2020
11/25/2020
Date
86.4(c)
86.55(c)
93.98(c)
95.33(c)
102.6(c)
Last
3 249 891
2 561 016
6 557 407
3 101 622
3 764 882
Volume
-3.90% +0.17% +8.58% +1.44% +7.63% Change
Sales 2020
550 M - -
Net income 2020
-310 M - -
Net cash position 2020
465 M - -
P/E ratio 2020
-17,6x
Yield 2020
-
Sales 2021
3 133 M - -
Net income 2021
984 M - -
Net cash position 2021
736 M - -
P/E ratio 2021
7,06x
Yield 2021
-
Capitalization
4 875 M 4 875 M -
EV / Sales 2020
8,02x
EV / Sales 2021
1,32x
Nbr of Employees
522
Free-Float
97,6%
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline...
Notations Surperformance© of Novavax, Inc.
Trading Rating : Investor Rating :
All news about NOVAVAX, INC.
News in other languages on NOVAVAX, INC.
Analyst Recommendations on NOVAVAX, INC.
Exclusive: Europe to pay less than U.S. for Pfizer vaccine under initial deal - source
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVAVAX, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
5
Average target price
186,20 $
Last Close Price
95,33 $
Spread / Highest target
134%
Spread / Average Target
95,3%
Spread / Lowest Target
-21,3%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
